Laura A. Dawson

Laura A. Dawson

Auto-generated profile, based on publicly available information

Laura A. Dawson

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
AMAshwathy S. Mathew
Ashwathy S. Mathew
LDLaura A. Dawson
Laura A. Dawson
The role of ablative stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has been evolving over the last few decades. SBRT has mostly been used in early stages of HCC, including few (≤ 3 in number) tumors, small tumours (< 3 cm in size), as well as larger tumours which are ineligible for other ablative modalities, mostly without vascular invasion. In early stage HCC, SBRT is used as a definitive treatment with curative intent or with intent to bridge to liver transplant. Retrospective and prospective institutional series document a high rate of local control (68– 95% at 3 years) following SBRT. This coupled with a low risk of toxicity makes this non-invasive ablative treatment an attractive option for patients who are ineligible for other ablative treatments. Small randomized studies of ablative radiation have also shown non-inferiority of radiation as compared to radiofrequency ablation (RFA). Currently, SBRT is widely available as a safe and effective liver directed therapy, although there is a need for more studies providing higher level evidence. This review gives a brief overview of SBRT and the evidence for its use in HCC patients with ablative intent.

20 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DHDaniel J. Herr
Daniel J. Herr
CWChang Wang
Chang Wang
MMMishal Mendiratta-Lala
Mishal Mendiratta-Lala
MMMartha Matuszak
Martha Matuszak
CMCharles S. Mayo
Charles S. Mayo
KCKyle Cuneo
Kyle Cuneo
Purpose: We hypothesized that optimizing the utility of stereotactic body radiotherapy (SBRT) based on the individual patient's probability for tumor control and risk of liver injury would decrease toxicity without sacrificing local control in patients with impaired liver function or tumors not amenable to thermal ablation. Patients and Methods: Patients with Child-Pugh (CP) A to B7 liver function with aggregate tumor size >3.5 cm, or CP ≥ B8 with any size tumor were prospectively enrolled on an Institutional Review Board–approved phase II clinical trial to undergo SBRT with baseline and midtreatment dose optimization using a quantitative, individualized utility-based analysis. Primary endpoints were change in CP score of ≥2 points within 6 months and local control. Protocol-treated patients were compared with patients receiving conventional SBRT at another cancer center using overlap weighting. Results: A total of 56 patients with 80 treated tumors were analyzed with a median follow-up of 11.2 months. Two-year cumulative incidence of local progression was 6.4% [95% confidence interval (CI, 2.4–13.4)]. Twenty-one percent of patients experienced treatment-related toxicity within 6 months, which is similar to the rate for SBRT in patients with CP A liver function. An analysis using overlap weighting revealed similar local control [HR, 0.69; 95% CI (0.25–1.91); P = 0.48] and decreased toxicity [OR, 0.26; 95% CI (0.07–0.99); P = 0.048] compared with conventional SBRT. Conclusions: Treatment of individuals with impaired liver function or tumors not amenable to thermal ablation with a treatment paradigm designed to optimize utility may decrease treatment-related toxicity while maintaining tumor control.

2 February 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
ASAmir H. Safavi
Amir H. Safavi
LDLaura A. Dawson
Laura A. Dawson
AMAruz Mesci
Aruz Mesci
• Stereotactic body radiotherapy (SBRT) is a safe and effective locoregional therapy for inoperable patients with HCC. • SBRT compares favorably with other local therapies in terms of local control, survival, morbidity, and cost-effectiveness. • SBRT should be considered and discussed in multidisciplinary management of appropriate HCC patients. • Advances in SBRT and novel combinations with systemic therapy may further widen the therapeutic index in HCC.

9 May 2025 in JHEP Reports
Verified
Journal Article
Open access
ZLZhihao Li
Zhihao Li
MYMichael Yan
Michael Yan
MCMarco P.A.W. Claasen
Marco P.A.W. Claasen
LRLuckshi Rajendran
Luckshi Rajendran
CMChristian Tibor Josef Magyar
Christian Tibor Josef Magyar
GSGonzalo Sapisochin
Gonzalo Sapisochin
Stereotactic body radiotherapy (SBRT) has emerged as a bridging/downstaging therapy for patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). This study evaluates the safety and outcomes of the use of SBRT in such patients. A retrospective review was conducted from 2004 to 2019 on 88 adult patients with HCC receiving SBRT as bridging/downstaging therapy. Endpoints, included treatment-related toxicities, liver function decline, and LT probability post SBRT, were analyzed using competing risk analysis. SBRT was used for bridging in 58 (66%) patients and downstaging in 30 (34%). Most patients had compensated liver function pre-SBRT and were treated with a median SBRT dose of 36 Gy in six fractions. Toxicities were mild (58% grade 1, 2% grade 2, and no grade 3 toxicities). Of the patients, 23% experienced a decline in liver function within 6 months post SBRT. The probability of LT post SBRT was 30% at 6 months, 61% at 1 year, and 73% at 2 years. Key predictors of LT post SBRT included model for end-stage liver disease (MELD) score, alpha-fetoprotein (AFP) level, and number and total tumor volume of HCC lesions. Overall, 61 (69%) patients underwent LT at a median of 6.3 months (IQR: 3.1–10.0) post SBRT, with major complications reported in 26% and an in-hospital mortality of 3%. Overall and recurrence-free survival at 1, 3, and 5 years post transplant were 88%, 83%, and 83% and 83%, 75%, 73%, respectively. The cumulative incidence of recurrence was significantly higher in the downstaging group compared with the bridging group (15%, 23%, and 32% vs. 7%, 15%, and 17% at 1, 3, and 5 years, respectively). Explant pathology revealed a 25% complete pathological response rate (bridging, 30%; downstaging, 12%). Our results showed that SBRT is a safe and effective bridging therapy for HCC. However, its role in downstaging is limited by lower response rates and higher recurrence, emphasizing the importance of patient selection. SBRT is an emerging therapy for patients with HCC awaiting LT, with limited data available on its safety and efficacy. Our study provides crucial insights for physicians and researchers, demonstrating that SBRT is a safe and effective option for bridging patients with HCC to transplantation. These findings are important for optimizing treatment strategies and providing patients with additional therapeutic options while awaiting transplantation. However, the lower response rates and higher recurrence in the downstaging group highlight the need for further research to improve patient selection and tailor treatments for optimal outcomes.

1 January 2008
Verified
Book Chapter
Closed access
NKNancy E. Kemeny
Nancy E. Kemeny
MKMargaret Kemeny
Margaret Kemeny
LDLaura Dawson
Laura Dawson

16 September 2024
Verified
Other
Open access
DHDaniel J. Herr
Daniel J. Herr
CWChang Wang
Chang Wang
MMMishal Mendiratta-Lala
Mishal Mendiratta-Lala
MMMartha Matuszak
Martha Matuszak
CMCharles S. Mayo
Charles S. Mayo
KCKyle Cuneo
Kyle Cuneo
Purpose: We hypothesized that optimizing the utility of stereotactic body radiation therapy (SBRT) based on the individual patient’s probability for tumor control and risk of liver injury would decrease toxicity without sacrificing local control in patients with impaired liver function or tumors not amenable to thermal ablation. Methods: Patients with Child-Pugh (CP) A to B7 liver function with aggregate tumor size >3.5 cm, or CP ≥ B8 with any size tumor were prospectively enrolled on an IRB approved phase II clinical trial to undergo SBRT with baseline and mid-treatment dose optimization using a quantitative, individualized utility-based analysis. Primary endpoints were change in CP score of ≥2 points within 6 months and local control. Protocol-treated patients were compared with patients receiving conventional SBRT at another cancer center using overlap weighting. Results: 56 patients with 80 treated tumors were analyzed with a median follow-up of 11.2 months. Two-year cumulative incidence of local progression was 6.4% (95% CI [2.4 – 13.4]). 21% of patients experienced treatment-related toxicity within 6 months, which is similar to the rate for SBRT in patients with CP A liver function. An analysis using overlap weighting revealed similar local control (HR 0.69, 95% CI [0.25-1.91], p = 0.48) and decreased toxicity (OR 0.26, 95% CI [0.07 – 0.99], p = 0.048) compared to conventional SBRT. Conclusion: Treatment of individuals with impaired liver function or tumors not amenable to thermal ablation with a treatment paradigm designed to optimize utility may decrease treatment-related toxicity while maintaining tumor control.